Skip to main content

Table 2 Median plasma level of inflammatory mediators in the 3 outcome groups

From: Multivariate projection method to investigate inflammation associated with secondary insults and outcome after human traumatic brain injury: a pilot study

 

Favorable outcome 6Ma

Unfavorable outcome 6Ma

Brain death

p value

IL-6

75.08 (31.81; 104.76)

169.95 (79.17; 188.3)

750 (602; 817)

<0.0001

IL-1β

0.66 (0.1; 1.05)

1.04 (0.6; 5.78)

1.32 (1.1; 1.97)

0.179

IL-1ra

66.92 (34.68; 226.97)

82.02 (70; 384.13)

532.66 (399; 2078.5)

0.078

IL-2

0.8 (0.8; 0.8)

0.8 (0.8; 0.8)

0.8 (0.8; 29.5)

0.041

IL-4

0.21 (0.01; 1.32)

0.6 (0.42; 5.31)

0.93 (0.8; 1.34)

0.304

IL-5

0.85 (0.13; 5.24)

1.14 (0.28; 15.36)

0.5 (0.29; 0.62)

0.415

IL-7

9.27 (1.38; 31.41)

45.4 (7.23; 141.17)

58.98 (16.25; 92.5)

0.215

IL-8

19.39 (3.99; 39.64)

60.29 (39; 104.58)

125.55 (37.02; 129)

0.013

IL-9

12.13 (2.35; 20.13)

32.91 (28; 46.86)

23.68 (20.5; 48.26)

0.022

IL-10

11.52 (1.57; 20.14)

20 (7.83; 57.02)

39.47 (12.37; 108.5)

0.029

IL-12

5.64 (0.81; 22.2)

11.82 (5.33; 42.48)

20.15 (17; 109.5)

0.043

IL-13

2.97 (0.62; 5.27)

7.4 (1.92; 11.27)

12.06 (5.78; 30)

0.047

IL-15

1.05 (0.06; 4.6)

0.06 (0.06; 6.16)

22.75 (3.7; 44.9)

0.001

IL-17

0.9 (0.9; 9.58)

49.06 (0.9; 75.33)

67.84 (28; 77.42)

0.162

Eotaxin

0.35 (0.35; 18.45)

19 (0.35; 29.31)

24.49 (10.5; 34.42)

0.094

basic FGF

3 (3; 24.45)

48.73 (3; 66.79)

49.61 (49.49; 131)

0.053

GCSF

50.95 (8.99; 138.65)

156.61 (107.5; 368.77)

483.17 (165; 491.86)

0.012

GMCSF

48 (2.29; 78.14)

39.18 (0.21; 91.61)

99.55 (83.84; 113)

0.084

IFNγ

4.15 (1.08; 25.73)

14.97 (11.99; 110.33)

25 (24.74; 29.08)

0.230

IP-10

111.06 (29; 256.19)

248.22 (215.09; 459.34)

2081.5 (528.43; 2232.08)

<0.0001

MCP1

162.16 (44.12; 307.83)

196.04 (77.78; 657.25)

690.82 (600; 2210)

0.001

MIP1α

1.5 (0.05; 2.33)

3.07 (1.2; 6.49)

3.71 (0.05; 11)

0.209

PDGFbb

141.57 (58.58; 229.67)

271.36 (195.11; 372.25)

104.64 (93.1; 210.46)

0.324

MIP1β

87.27 (55.98; 134.88)

123.05 (98; 133.01)

416 (275.42; 594)

0.001

RANTES

5193.61 (1952.35; 8553.06)

8903.57 (4098.28; 11442.69)

3570.05 (2309.71; 3831.31)

0.564

TNF-RI

1252.27 (522.38; 1568.18)

1320.45 (970.33; 1513.64)

1957 (1543.13; 2679)

0.394

TNF-RII

2190 (730; 4723.08)

4161.9 (3707.69; 5368.54)

5678 (4919; 6564.78)

0.021

TNFα

8 (5.58; 50.59)

5.5 (3.9; 93.05)

9.78 (8.12; 18.45)

0.262

VEGF

6.04 (0.08; 27.12)

29.79 (8.12; 42.22)

60.22 (34.28; 322)

0.002

IL6/IL10

57 (30.39; 324.61)

59.24 (39.89; 104.28)

277.07 (126.7; 1598.89)

0.765

IL1ra/IL1β

7.92 (3.66; 19.53)

8.9 (3.77; 22.4)

27.11 (5; 32.29)

0.064

  1. aAt 6 months. Values are median (IQR). IQR interquartile range. Significant correlations are reported in italics